Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus

Biology of Reproduction

Volumn 72, Issue 4, 2005, Pages 830-841

  Helvering, L M ^a   Adrian, M D ^a   Geiser, A G ^a   Estrem, S T ^a   Wei, T ^a   Huang, S ^a   Chen, P ^a   Dow, E R ^a   Calley, J N ^a   Dodge, J A ^a   Grese, T A ^a   Jones, S A ^a   Halladay, D L ^a   Miles, R R ^a   Onyia, J E ^a   Ma, Y L ^a   Sato, M ^a   Bryant, H U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Estradiol receptor; Female reproductive tract; Mechanisms of hormone action; Uterus; Vagina

Indexed keywords

CENTCHROMAN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; GELATINASE A; LASOFOXIFENE; MESSENGER RNA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL DEATH; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ESTROGEN ACTIVITY; FEMALE; GENE CONTROL; GENE EXPRESSION; METABOLISM; NONHUMAN; NORTHERN BLOTTING; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RAT; UTERUS; UTERUS CONTRACTION;

ANIMALS; ESTROGENS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIECTOMY; PYRROLIDINES; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES; UTERUS;

EID: 20144383817     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod.104.034595     Document Type: Article

References (70)

1. Sato M, Grese T, Dodge J, Bryant HU, Turner CH. Emerging therapies for the prevention of treatment of postmenopausal osteoporosis. J Med Chem 1999; 42:1-24.
2. Ke HZ, Chen HK, Simmons A, Qi H, Crawford DT, Pirie CM, Chidsey-Frink KL, Ma YF, Jee WSS, Thompson DD. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 1997; 20: 31-39.
3. Galbiati E, Caruso PL, Amari G, Armani E, Ghirardi S, Delcanale M, Civelli M. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl] methyl]-2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue. J Pharm Exp Ther 2002; 300:802-809.
4. Ke HZ, Foley FL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004; 145:1996-2005.
5. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L. Uterine effects of three-year raloxifene therapy in postmenopausal women underage 60. Obstet Gynecol 2000; 95:104-110.
6. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000; 95:95-103.
7. Goldstein SR, Neven P, Zhou L, Taylor YL, Ciaccia AV, Plouffe L Jr. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 2001; 98:91-96.
8. Waetjen LE, Brown JS, Modelska K, Balckwell T, Vittinghoff E, Cummings SR. Effect of raloxifene on urinary incontinence: a randomized controlled trial. Obstet Gynecol 2004; 103:261-266.
9. Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004; 164: 871-879.
10. Klutke JJ, Bergman A. Hormonal influence on the urinary tract. Urol Clin North Am 1995; 22:629-639.
11. Committee on Patient Education of the American College of Obstetrics and Gynecologists. Pelvic Support Problems. Washington, DC: American College of Obstetricians and Gynecologists; 1995.
12. Samuelsson E, Victor A, Svardsudd K. Determinants of urinary incontinence in a population of young and middle-aged women. Acta Obstet Gynecol Scand 2000; 79:208-215.
13. Kenton K, Sadowski D, Shott S, Brubaker L. A comparison of women with primary and recurrent pelvic prolapse. Am J Obstet Gynecol 1999; 180:1415-1418.
14. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapies and risk of developing urinary incontinence. Obstet Gynecol 2004; 103:254-260.
15. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T. Postmenopausal hormones and incontinence: the heart and estrogen/progestin replacement study. Obstet Gynecol 2001; 97:116-120.
16. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002; 187:521-527.
17. Warming L, Christoffersen C, Rus BJ, Stakkestad JA, Delmas PD, Christiansen C. Adverse effects of a SERM (levormeloxifene) safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003; 44:189-199.
18. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002; 296:1642-1644.
19. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifene, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996; 8:905-912.
20. Salman M, Ray S, Anand N, Argarwal AK, Singh MM, Setty SS, Kamboj VP. Studies in antifertility agents. 50. Stereoselective binding of D- and L-centchromans to estrogen receptors and their antifertility activity. J Med Chem 1986; 29:1801-1803.
21. Rosati RL, Jardine PD, Cameron KO, Thompson DD, Ke HZ, Toler SM, Brown TA, Pan LC, Ebbinghaus CF, Reinhold AR, Elliott NC, Newhouse BN, Tjoa CM, Sweetnam PM, Cole MJ, Arriola MW, Gauthier JW, Crawford DT, Nickerson DF, Pirie CM, Qi H, Simmons HA, Tkalcevic GT. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydro-naphthalene. J Med Chem 1998; 41:2928-2931.
22. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A 1984; 81:1991-1995.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995; 57:289-300.
24. Jolliffe IT. Outlier detection, influential observations, and robust estimation. In: Jolliffe IT (ed.), Principal Component Analysis, 2nd ed. New York: Springer-Verlag; 2002:232-268.
25. Venables WN, Ripley BD. Modern Applied Statistics with S-PLUS. New York: Springer-Verlag; 1997:41-89.
26. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95:14863-14868.
27. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A 1999; 96:2907-2912.
28. Kent WJ. BLAT-the BLAST-like alignment tool. Genome Res 2002; 12:656-664.
29. Hodges PE, Carrico PM, Hogan JD, O'Neill KE, Owen JJ, Mangan M, Davis BP, Brooks JE, Garrels JI. Annotating the human proteome: the Human Proteome Survey Database (HumanPSD™) and an indepth target database for G protein-coupled receptors (GPCR-PD) from Incyte Genomics. Nucleic Acids Res 2002; 30:137-141.
30. Gene Ontology Consortium. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004; 32:D258-D261.
31. Too CKL, Kong JK, Greenwood FC, Bryant-Greenwood GD. The effect of estrogen and relaxin on uterine and cervical enzymes: collagenase, proteoglycanase and β-glycuronidase. Acta Endocrinol 1986; 111:394-403.
32. Crabbe T, Smith B, O'Connell J, Docherty A. Human progelatinase A can be activated by matrilysin. FEBS Lett 1994; 345:14-16.
33. Sang QA, Bodden MK, Windson LJ. Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin. J Protein Chem 1996; 15:243-253.
34. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 2003; 200:448-464.
35. Woessner JF. Regulation of matrilysin in the rat uterus. Biochem Cell Biol 1996; 74:777-784.
36. Kuusisto E, Suuronen T, Salminen A. Ubiqutin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells. Biochem Biophys Res Comm 2001; 280:223-228.
37. Morita H, Isobe K, Cai Z, Miyazuki T, Matsumoto Y, Shinzato T, Yoshikai Y, Kimata K, Maeda K. Thy-1 antigen mediates apoptosis of rat glomerular cells in vitro and in vivo. Nephron 1996; 73:293-298.
38. Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ, Filmus J. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 1998; 141:1407-1414.
39. Cano-Gauci DF, Song HH, Yang H, McKerlie C, Choo B, Shi W, Pullano R, Piscione TD, Grisaru S, Soon S, Sedlackova L, Tanswell AK, Mak TW, Yeger H, Lock-wood GA, Rosenblum ND, Filmus J. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 1999; 146:255-264.
40. Yang JY, Widmann C. The RasGAP N-terminal fragment generated by caspase cleavage protects cells in a Ras/PI3K/Akt-dependent manner that does not rely on NFκB activation. J Biol Chem 2002; 277: 14641-14646.
41. Tomomura M, Fernandez-Gonzales A, Yano R, Yuzaki M. Characterization of the apoptosis-associated tyrosine kinase (AATYK) expressed in the CNS. Oncogene 2001; 20:1022-1032.
42. Ozaki T, Nakamura Y, Enomoto H, Hirose M, Sakiyama S. Overexpression of DAN gene product in normal rat fibroblasts causes a retardation of entry into the S phase. Cancer Res 1995; 55:895-900.
43. Larsen M, Ressler SJ, Lu B, Gerdes MJ, McBride L, Dang TD, Rowley DR. Molecular cloning and expression of ps20 growth inhibitor. J Biol Chem 1998; 273:4574-4584.
44. Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Fi L, Roth JA, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 2000; 19:4432-4436.
45. Putzer P, Breuer P, Gotz W, Gross M, Kubler B, Scharf JG, Schuller AG, Hartmann H, Braulke T. Mouse insulin-like growth factor binding protein-6: expression, purification, characterization and histochemical localization. Mol Cell Endocrinol 1998; 137:69-78.
46. Kato M, Ishizaki A, Hellman U, Wernstedt C, Kyogoku M, Miyazono K, Heldin CH, Funa K. A human keratinocyte cell line produces two autocrine growth inhibitors, transforming growth factor-beta and insulin-like growth factor binding protein-6, in a calcium- and cell density-dependent manner. J Biol Chem 1995; 270:12373-12379.
47. Westergren-Thorssen G, Norman M, Bjornsson S, Endresen U, Stjernholm Y, Ekman G, Malmstrom A. Differential expressions of mRNA for proteoglycans, collagens and transforming growth factor β in the human cervix during pregnancy and involution. Biochim Biophys Acta 1998; 1406:203-213.
48. San Martin S, Zorn TMT. The small proteoglycan biglycan is associated with thick collagen fibrils in the mouse decidua. Cell Mol Biol 2003; 49:673-678.
49. Ameye L, Aria D, Jepsen K, Oldberg A, Xu T, Young MF. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J 2002; 16:673-680.
50. Kessler E, Adar R. Type I procollagen C-proteinase from mouse fibroblasts. Purification and demonstration of a 55-kDa enhancer glycoprotein. Eur J Biochem 1989; 186:115-121.
51. Mott JD, Thomas CL, Rosenbach MT, Takahara K, Greenspan DS, Banda MJ. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J Biol Chem 2000; 275:1384-1390.
52. Scott IC, Clark TG, Takahara K, Hoffman GG, Greenspan DS. Structural Organization and expression patterns of the human and mouse genes for the type I procollagen COOH-terminal proteinase enhancer protein. Genomics 1999; 55:229-234.
53. Ligon AH, Scott IC, Takahara K, Greenspan DS, Morton CC. PCOLCE deletion and expression analysis in uterine leiomyomata. Cancer Genet Cytogenet 2002; 137:133-137.
54. Layne MD, Yet SF, Maemura K, Hsieh CM, Bernfield M, Perrella MA, Lee ME. Impaired abdominal wall development and deficient wound healing in mice lacking aortic carboxypeptidase-like protein. Mol Cell Biol 2001; 21:5256-5261.
55. Layne MD, Endege WO, Jain MK, Yet SF, Hsieh CM, Chin MT, Perralla MA, Blanar MA, Haber E, Lee ME. Aortic carboxypeptidase-like protein, a novel protein with discoidin and carboxypeptidase-like domains, is up-regulated during vascular smooth muscle cell differentiation. J Biol Chem 1998; 273:15654-15660.
56. Norton PA. Pelvic floor disorders: the role of fascia and ligaments. Clin Obstet Gynecol 1993; 36:926-938.
57. Liapis A, Bakas P, Pafiti A, Hassiakos D, Frangos-Plemenos M, Creatsas G. Changes in the quantity of collagen type I in women with genuine stress incontinence. Urol Res 2002; 28:323-326.
58. Jackson S, James M, Abrams P. The effect of estradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. Br J Obstet Gynaecol 2002; 109:339-344.
59. Ulmsten U, Ekman G, Giertz G, Malmstrom A. Different biochemical composition of connective tissue in continent and stress incontinent women. 1987; 66:455-457.
60. Rechberger T, Donica H, Baranowski W, Jakowicki J. Female urinary stress incontinence in terms of connective tissue biochemistry. Eur J Obstet Gynecol Reprod Biol 1993; 49:187-191.
61. Keane DP, Sims TJ, Abrams P, Bailey AJ. Analysis of collagen status in premenopausal nulliparous women with genuine stress incontinence. Br J Obstet Gynaecol 1997; 104:994-998.
62. Falconer C, Blomgren B, Johansson O, Ulmsten U, Malmstrom A, Westergren-Thorsson G, Ekman-Ordeberg G. Different organization of collagen fibrils in stress-incontinent women of fertile age. Acta Obstet Gynecol Scand 1998; 77:87-94.
63. Goepel C, Hefler L, Methfessel HD, Koelbl H. Periurethral connective tissue status of postmenopausal women with genital prolapse with and without stress incontinence. Acta Obstet Gynecol Scand 2003; 82: 659-664.
64. Lang J, Zhu LO, Sun A, Chen J. Clinical study on collagen and stress urinary incontinence. Clin Exp Obstet Gynecol 2002; 29:180-182.
65. Takano CC, Girao MJBC, Sartori MGF, Castro RA, Arruda RM, Simoes MJ, Baracat EC, Rodrigues de Lima G. Analysis of collagen in parametrium and vaginal apex of women with and without uterine prolapse. Int Urogynecol J 2002; 13:342-345.
66. Jackson SR, Avery NC, Tarlton JF, Eckford SD, Abrams P, Bailey AJ. Changes in metabolism of collagen in genitourinary prolapse. Lancet 1996; 347:1658-1661.
67. Wong MY, Harmanli OH, Agar M, Dandolu V, Grody MH. Collagen content of nonsupport tissue in pelvic organ prolapse and stress urinary incontinence. Am J Obstet Gynecol 2003; 189:1597-1599.
68. Versi E, Cardozo L, Brincat M, Cooper D, Montgomery J, Studd J. Correlation of urethral physiology and skin collagen in postmenopausal women. Br J Obstet Gynecol 1988; 95:147-152.
69. Thom DH, Brown JS. Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiological literature. J Am Geriatr Soc 1998; 46:1411-1417.
70. Curry TE, Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003; 24:428-465.